Kurt R. Nielsen, Ph.D., has been appointed president and chief executive officer of Pharmaceutics International, Inc. (Pii), a CDMO headquartered in Hunt Valley, MD. Dr. Abidi, founder and former chief executive officer of Pii, will transition into an advisory role and as the executive chairman.
 

Dr. Nielsen is a pharmaceutical executive with more than 20 years of diverse experience, most recently serving as  president of Lupin Somerset, responsible for all generic and branded products. Prior to Lupin, he was vice president, U.S. Development, Portfolio and Launch Management at Sandoz Inc., where he was accountable for the U.S. development of generic, OTC and specialty brand products. Dr. Nielsen has also held positions at Catalent, where he was senior vice president of R&D and chief technology officer, and URL Pharma where he was the executive vice president, Pharmaceuticals. 
 
Dr. Nielsen said, “As we enter the 25^th year of service to our valued partners, Pii is well-positioned to outpace the growth of the CDMO market with our depth and breadth of expertise in development and reliable supply of Branded, Specialty Generic and OTC products.”
 
“The appointment of Dr. Nielsen to the position of president and chief executive officer reflects a further commitment to growth, building upon Pii’s legacy of success, his diverse experiences, proven leadership and industry insights will be instrumental in achieving our strategic objectives,” said Dr. Abidi, Pii’s founder and executive chairman of the Board of Directors.